A short while ago, the company reported the Board voted today to maintain the quarterly cash dividend of $0.46 per share of common stock, payable February 18, 2012, to stockholders of record at the close of business, January 20, 2012.
The company said "Across the company this year, we have remained focused on our objectives and that gives us confidence in our ability to deliver on our business goals for 2011. Combined with our belief in our 2015 strategic plan, today we are reaffirming our outlook... 2011 sales and revenues are expected to be about $58 bln vs $58.3 consensus. The 2011 outlook includes about $2 billion in Bucyrus sales. Excluding the impact of the Bucyrus acquisition, we expect sales and revenues will be about $56 billion in 2011. We expect 2011 profit of about $6.75 per share vs $7.05 consensus. The outlook includes a negative impact from the acquisition of Bucyrus of about $0.50 per share, which is unchanged from the previous outlook. Excluding the impact of Bucyrus, we expect 2011 profit of about $7.25 per share. We are close to finalizing our business plans for 2012, and in late January when we issue our full-year results for 2011, we will issue a more detailed 2012 outlook. The preliminary outlook for 2012 sales and revenues is based on improving but slow growth in the developed parts of the world with continuing improvement in sales from what are currently low levels. We expect sales and revenues to improve 10 to 20 percent (current consensus calls for 15% rev growth) from the 2011 outlook of about $58 billion. The 2012 outlook includes a full year of Bucyrus-related sales of about $5 billion, up from a partial year of about $2 billion in 2011..."






